A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Public ClinicalTrials.gov record NCT03625505. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
A dose-escalation study evaluating the safety, tolerability, pharmacokinetics (PK) and efficacy of venetoclax, in combination with gilteritinib, in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy.
Study identification
- NCT ID
- NCT03625505
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 18, 2018 (Actual)
- Primary completion
- Aug 31, 2021 (Actual)
- Completion
- Aug 31, 2021 (Actual)
- Last update posted
- Sep 14, 2021
2018 – 2021
United States locations
- U.S. sites
- 11
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| David Geffen School of Medicin /ID# 200166 | Los Angeles | California | 90095 | — |
| UC San Francisco Medical Center-Parnassus /ID# 200205 | San Francisco | California | 94143-2202 | — |
| Sylvester Comprehensive Cancer /ID# 200268 | Miami | Florida | 33136-1002 | — |
| Northwestern Memorial Hospital /ID# 200230 | Chicago | Illinois | 60611-2927 | — |
| Norton Cancer Institute /ID# 200623 | Louisville | Kentucky | 40202-3700 | — |
| Johns Hopkins University /ID# 200349 | Baltimore | Maryland | 21287 | — |
| Mayo Clinic - Rochester /ID# 200346 | Rochester | Minnesota | 55905-0001 | — |
| Hackensack Univ Med Ctr /ID# 200229 | Hackensack | New Jersey | 07601 | — |
| Weill Cornell Medical College /ID# 200109 | New York | New York | 10065 | — |
| Hosp of the Univ of Penn /ID# 200348 | Philadelphia | Pennsylvania | 19104 | — |
| MD Anderson Cancer Center at Texas Medical Center /ID# 206686 | Houston | Texas | 77030-4000 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03625505, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2021 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03625505 live on ClinicalTrials.gov.